Quince Therapeutics Files 8-K on Security Holder Vote
Ticker: QNCX · Form: 8-K · Filed: Jun 5, 2025 · CIK: 1662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance, filing-update
Related Tickers: QNCX
TL;DR
Quince Therapeutics had a shareholder vote on June 4th, details in new 8-K.
AI Summary
Quince Therapeutics, Inc. (formerly Cortexyme, Inc.) filed an 8-K on June 5, 2025, reporting on a matter submitted to a vote of its security holders on June 4, 2025. The company, incorporated in Delaware with its principal executive offices in South San Francisco, California, operates in the biological products sector.
Why It Matters
This filing indicates a significant event involving shareholder decisions, which could impact the company's strategic direction or governance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating immediate financial distress or major operational changes.
Key Numbers
- 001-38890 — SEC File Number (Identifies the company's filing history with the SEC)
- 90-1024039 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Quince Therapeutics, Inc. (company) — Registrant
- Cortexyme, Inc. (company) — Former company name
- June 4, 2025 (date) — Date of earliest event reported
- June 5, 2025 (date) — Date of report
- South San Francisco, California (location) — Principal executive offices
FAQ
What specific matter was submitted to a vote of Quince Therapeutics' security holders on June 4, 2025?
The filing does not specify the exact matter voted upon, only that a submission to a vote of security holders occurred on June 4, 2025.
When did Quince Therapeutics change its name from Cortexyme, Inc.?
The date of the name change from Cortexyme, Inc. to Quince Therapeutics, Inc. was January 4, 2016.
What is Quince Therapeutics' primary business sector?
Quince Therapeutics, Inc. is in the Biological Products (No Diagnostic Substances) sector, SIC code 2836.
Where are Quince Therapeutics' principal executive offices located?
The principal executive offices of Quince Therapeutics, Inc. are located at 601 Gateway Boulevard, Suite 1250, South San Francisco, California 94080.
What is the SEC file number for Quince Therapeutics?
The SEC file number for Quince Therapeutics, Inc. is 001-38890.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 regarding Quince Therapeutics, Inc. (QNCX).